Navigation Links
Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
Date:6/30/2008

Par to Begin Shipping Dronabinol Soft Gel Capsules Immediately

WOODCLIFF LAKE, N.J., June 30 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for dronabinol, a generic version of Solvay Pharmaceutical's Marinol(R), a CIII controlled substance. This product is approved to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments and is available in 2.5mg, 5 mg and 10 mg strengths. Annual U.S. sales of Marinol are approximately $190 million, according to IMS Health data. Par will begin shipping all strengths of dronabinol soft gel capsules to the trade immediately.

Under the terms of a license and distribution agreement with SVC Pharma LP, an affiliate of Rhodes Technologies, Par has the right to market, sell and distribute dronabinol in the U.S. Par and SVC Pharma LP will share profits equally from the sales of the product.

Important information about dronabinol soft gel capsules

Dronabinol is contraindicated in any patient who has a history of hypersensitivity to any cannabinoid, sesame oil or any ingredients in dronabinol capsules. Warn patients not to drive, operate machinery, or engage in hazardous activity until they establish they can tolerate dronabinol and perform such tasks.

Dronabinol should be used with caution in patients with a history of seizure disorder; patients with cardiac disorders; patients with a history of substance abuse (including alcohol abuse or dependence); patients with mania, depression, or schizophrenia (along with careful psy
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... Switzerland’s MS Tûranor PlanetSolar , the ... record for a transatlantic crossing by a solar electric ... 25, 2013, the solar powered boat sailed 2,867miles (5,310 ... of 5.3 knots before reaching Marigot, St. Martin, in ... first-of-its-kind catamaran completed this year’s passage across the Atlantic ...
(Date:5/19/2013)... The JM Internet Group (web: jm-seo.org), a leader ... that the company's YouTube channel on SEO tips ... YouTube. The company uses YouTube as a way to ... for small businesses with much success. , "I love ... for their SEO strategies", explained Jason McDonald, director of ...
(Date:5/17/2013)... 2013 Topricin Pain Relief and ... been listed among nationally recommended over-the-counter (OTC) health ... by "U.S. News" Health in collaboration with "Pharmacy ... “No. 1 Pharmacists Recommended designation” in the “Topical ... brands, and is the only homeopathic formula to ...
(Date:5/17/2013)... 17, 2013 Dr. Sparano is Professor ... Health at the Albert Einstein College of Medicine and ... Montefiore Medical Center. He is also Associate Director ... leads the Einstein Breast Cancer Working Group, a multidisciplinary ... cancer research. He also serves as Vice Chair of ...
Breaking Biology Technology:MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3
... May 9 ,Takeda Pharmaceutical Company Limited, "Takeda", (TSE: ... ) today announced the,successful completion of Takeda,s cash ... to acquire all outstanding shares,of Millennium common stock ... period for the tender offer expired at 12:00,midnight, ...
... May 8 Alsius Corporation,(Nasdaq: ALUS ), ... for critically ill patients, today,announced that it will ... quarter results and provide a corporate update. Bill ... host the call beginning at,1:30 p.m. Pacific Time ...
... May 8 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) ... 2008 at,8:30 a.m. EDT to discuss the first quarter ... Officer of the Company, will host,the call. Keryx will ... release to be issued prior to the call., ...
Cached Biology Technology:Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 2Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 3Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 4Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 5Alsius Corporation to Host First Quarter 2008 Financial Results Conference Call on May 15, 2008 2Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT 2
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... China---- Why Tibetan antelope can live at elevations ... collaborative research published in Nature Communications , ... provide evidence that some genetic factors may be ... environments. The data in this work will also ... the biology of other ruminant species. , The ...
(Date:5/17/2013)... climate change may have little impact on many ... recent studies that predict their widespread extinction in ... appear in the journal Global Change Biology ... creature thought to be doomed: http://onlinelibrary.wiley.com/doi/10.1111/gcb.12253/abstract ... forest lizards, will be hard hit by climate ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Climate change may have little impact on tropical lizards 2
... A research team at Worcester Polytechnic Institute (WPI) ... Institutes of Health (NIH) for a project aimed at ... into stem-like cells. If successful, the research could result ... tissue lost to injury, growing new organs, and curing ...
... Erec Stebbins, associate professor at The Rockefeller University, has ... Institutes of Health for a project aimed at exploiting ... into specific cells for therapeutic purposes. The award, which ... by the NIH September 3. The EUREKA program ...
... two Michigan universities have joined technical and clinical ... and computer algorithms to work in the sleep ... that a new approach to analyzing sleep fragmentation ... Joseph W. Burns, a research scientist ...
Cached Biology News:NIH EUREKA award funds research at WPI aimed at turning adult skin cells into stem-like cells 2NIH EUREKA award funds research at WPI aimed at turning adult skin cells into stem-like cells 3NIH EUREKA award funds research at WPI aimed at turning adult skin cells into stem-like cells 4C. Erec Stebbins awarded prestigious EUREKA grant 2What a sleep study can reveal about fibromyalgia 2What a sleep study can reveal about fibromyalgia 3
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Macrophage-stimulating protein receptor...
Biology Products: